Yttrium‐90 radioembolization vs sorafenib for intermediate‐locally advanced hepatocellular carcinoma: a cohort study with propensity score analysis

Publisher： John Wiley & Sons Inc

E-ISSN： 1478-3231|35|3|1036-1047

ISSN： 1478-3223

Source： LIVER INTERNATIONAL (ELECTRONIC), Vol.35, Iss.3, 2015-03, pp. : 1036-1047

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Reply to: “Sorafenib or 90Y loaded resin microsphere radioembolization for locally‐advanced hepatocellular carcinoma, what should we trust?”

By  

LIVER INTERNATIONAL (ELECTRONIC), Vol. 35, Iss. 6, 2015-06 ,pp. : 1780-1781

John Wiley & Sons Inc

Access to resources Recommend Favorite

Sorafenib‐ or 90Y‐loaded resin microsphere radioembolization for locally advanced hepatocellular carcinoma, what should we trust?

By  

LIVER INTERNATIONAL (ELECTRONIC), Vol. 35, Iss. 6, 2015-06 ,pp. : 1779-1780

John Wiley & Sons Inc

Access to resources Recommend Favorite

In intermediate stage hepatocellular carcinoma: radioembolization with yttrium 90 or chemoembolization?

By  

LIVER INTERNATIONAL (ELECTRONIC), Vol. 35, Iss. 2, 2015-02 ,pp. : 627-635

John Wiley & Sons Inc

Access to resources Recommend Favorite

Half‐dose sorafenib for HCC

By  

HEPATOLOGY RESEARCH, Vol. 45, Iss. 3, 2015-03 ,pp. : 279-287

John Wiley & Sons Inc

Access to resources Recommend Favorite

Safety and toxicity of radioembolization plus Sorafenib in advanced hepatocellular carcinoma: analysis of the European multicentre trial SORAMIC

By  

LIVER INTERNATIONAL (ELECTRONIC), Vol. 35, Iss. 2, 2015-02 ,pp. : 620-626

John Wiley & Sons Inc

Access to resources Recommend Favorite